Ping Chen, San Diego, CA (US); Sujin Cho-Schultz, San Diego, CA (US); Judith Gail Deal, San Diego, CA (US); Gary Michael Gallego, San Diego, CA (US); Mehran Jalaie, San Diego, CA (US); Robert Steven Kania, Del Mar, CA (US); Sajiv Krishnan Nair, San Diego, CA (US); Sacha Ninkovic, San Diego, CA (US); Suvi Tuula Marjukka Orr, San Diego, CA (US); and Cynthia Louise Palmer, La Mesa, CA (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Dec. 7, 2021, as Appl. No. 17/544,303.
Application 17/544,303 is a continuation of application No. 16/942,209, filed on Jul. 29, 2020, granted, now 11,220,494.
Application 16/942,209 is a continuation of application No. 16/391,836, filed on Apr. 23, 2019, granted, now 10,766,884, issued on Sep. 8, 2020.
Claims priority of provisional application 62/826,609, filed on Mar. 29, 2019.
Claims priority of provisional application 62/750,454, filed on Oct. 25, 2018.
Claims priority of provisional application 62/663,096, filed on Apr. 26, 2018.
Prior Publication US 2022/0089580 A1, Mar. 24, 2022
1. A compound, which is 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-threo-pentitol, wherein one or more hydrogen atoms are replaced by deuterium.